SI2556091T1 - Protitelo, prepoznavajoče humani inhibitorski faktor levkemije (LIF) in uporaba anti-LIF protiteles pri zdravljenju bolezni, povezanih z neželenim širjenjem celic - Google Patents

Protitelo, prepoznavajoče humani inhibitorski faktor levkemije (LIF) in uporaba anti-LIF protiteles pri zdravljenju bolezni, povezanih z neželenim širjenjem celic

Info

Publication number
SI2556091T1
SI2556091T1 SI201131028A SI201131028A SI2556091T1 SI 2556091 T1 SI2556091 T1 SI 2556091T1 SI 201131028 A SI201131028 A SI 201131028A SI 201131028 A SI201131028 A SI 201131028A SI 2556091 T1 SI2556091 T1 SI 2556091T1
Authority
SI
Slovenia
Prior art keywords
lif
treatment
cell proliferation
diseases associated
inhibitory factor
Prior art date
Application number
SI201131028A
Other languages
English (en)
Inventor
Suarez Joan Seoane
Folgueira Judit Anido
Borderias Andrea Saez
Original Assignee
Fundacio Privada Institut d'Investigacio Oncologica de Vall D'Hebron (VH10)
Fundacio Privada Institucio Catalana De Recerca I Estudis Avancants
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Institut d'Investigacio Oncologica de Vall D'Hebron (VH10), Fundacio Privada Institucio Catalana De Recerca I Estudis Avancants filed Critical Fundacio Privada Institut d'Investigacio Oncologica de Vall D'Hebron (VH10)
Publication of SI2556091T1 publication Critical patent/SI2556091T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5415—Leukaemia inhibitory factor [LIF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Radiology & Medical Imaging (AREA)
SI201131028A 2010-04-05 2011-04-05 Protitelo, prepoznavajoče humani inhibitorski faktor levkemije (LIF) in uporaba anti-LIF protiteles pri zdravljenju bolezni, povezanih z neželenim širjenjem celic SI2556091T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10380049A EP2371860A1 (en) 2010-04-05 2010-04-05 Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
PCT/EP2011/055253 WO2011124566A1 (en) 2010-04-05 2011-04-05 Antibody recognizing human leukemia inhibitory factor (lif) and use of anti-lif antibodies in the treatment of diseases associated with unwanted cell proliferation
EP11715676.0A EP2556091B1 (en) 2010-04-05 2011-04-05 Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation

Publications (1)

Publication Number Publication Date
SI2556091T1 true SI2556091T1 (sl) 2017-02-28

Family

ID=42338260

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201131028A SI2556091T1 (sl) 2010-04-05 2011-04-05 Protitelo, prepoznavajoče humani inhibitorski faktor levkemije (LIF) in uporaba anti-LIF protiteles pri zdravljenju bolezni, povezanih z neželenim širjenjem celic

Country Status (25)

Country Link
US (3) US8926956B2 (sl)
EP (3) EP2371860A1 (sl)
JP (2) JP6289906B2 (sl)
KR (5) KR20190061098A (sl)
CN (2) CN109320609A (sl)
AU (1) AU2011237922B2 (sl)
BR (1) BR112012025517B1 (sl)
CA (1) CA2797257A1 (sl)
CY (1) CY1119451T1 (sl)
DK (1) DK2556091T3 (sl)
EA (2) EA202092276A3 (sl)
ES (1) ES2608699T3 (sl)
HK (3) HK1180702A1 (sl)
HR (1) HRP20161736T1 (sl)
HU (1) HUE030578T2 (sl)
IL (3) IL222270A (sl)
LT (1) LT2556091T (sl)
MX (2) MX365054B (sl)
PL (1) PL2556091T3 (sl)
PT (1) PT2556091T (sl)
RS (1) RS55539B1 (sl)
SG (1) SG184429A1 (sl)
SI (1) SI2556091T1 (sl)
SM (1) SMT201600468T1 (sl)
WO (1) WO2011124566A1 (sl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3117833T3 (en) * 2005-07-19 2019-03-18 Stemgen S P A Inhibition of Tumor-rich Potential of Tumor Stem Cells with LIF
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
EP3049110A2 (en) * 2013-09-23 2016-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for targeting tumor microenvironment and for preventing metastasis
TWI486172B (zh) * 2013-11-08 2015-06-01 Univ Chang Gung 鼻咽癌治療的醫藥
CA2958685A1 (en) * 2014-09-10 2016-03-17 The Regents Of The University Of California Targeting k-ras-mediated signaling pathways and malignancy by anti-hlif antibodies
CA2981173C (en) 2015-03-23 2024-01-02 Evestra, Inc. Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents
EP3173483A1 (en) * 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
IL294088B2 (en) 2016-12-19 2023-10-01 Medimmune Ltd Antibodies against LIF and their uses
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US20210130453A1 (en) 2018-04-12 2021-05-06 Medimmune Limited Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
US20220064279A1 (en) * 2018-05-14 2022-03-03 Medimmune Limited Antibodies against lif and dosage forms thereof
CN112703202A (zh) * 2018-06-18 2021-04-23 免疫医疗有限公司 用于改善患有癌症的个体对抗lif抗体治疗的反应的方法
SG11202012576QA (en) * 2018-06-18 2021-01-28 Medimmune Ltd Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
MX2022003762A (es) * 2019-09-29 2022-06-24 Jacobio Pharmaceuticals Co Ltd Molécula de unión específica para el factor inhibidor de la leucemia (lif) y uso de la misma.
CN111020030A (zh) * 2019-12-03 2020-04-17 中山大学 一种骨肉瘤干细胞标志物及其应用、试剂盒
CN111378036B (zh) * 2020-01-09 2021-08-10 北京浩古元方生物医药科技有限公司 一种抗人白血病抑制因子单克隆抗体的制备方法及其应用
CN112294812B (zh) * 2020-11-18 2022-08-16 新乡医学院 一种小分子抑制剂在制备抗肿瘤药物方面的应用
CN114672460B (zh) * 2021-12-21 2023-06-23 中国人民解放军军事科学院军事医学研究院 一种靶向cd44的异质型cic细胞模型的制备方法及应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB9004890D0 (en) 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
JPH05304986A (ja) 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
AU4231393A (en) 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
WO1993023665A1 (en) 1992-05-15 1993-11-25 Re/Map Incorporated Electromagnetic shielding for a liquid conditioning device
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
DE69635630T2 (de) * 1995-04-24 2006-08-10 Genentech, Inc., South San Francisco Verwendung eines Leukämie-hemmenden Faktor Antagonisten
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
CA2359067C (en) 1999-01-15 2017-03-14 Genentech, Inc. Polypeptide variants with altered effector function
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP1497445A2 (en) 2002-04-01 2005-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
EP2236614A3 (en) * 2002-08-15 2011-01-26 Genzyme Corporation Brain endothelial cell expression patterns
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005030803A1 (en) 2003-09-29 2005-04-07 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
EP1752536A4 (en) 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
EP1612558A1 (en) 2004-06-30 2006-01-04 Academisch Ziekenhuis Leiden Method for detecting gluten
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
JP2010505876A (ja) 2006-10-04 2010-02-25 ザ スクリプス リサーチ インスティテュート ヒトメタニューモウイルスを中和するヒト抗体
CN101440128A (zh) * 2007-11-21 2009-05-27 中国人民解放军第二军医大学 人脑胶质瘤中差异表达的蛋白及其用途
WO2010054499A1 (en) * 2008-11-11 2010-05-20 Telefonaktiebolaget L M Ericsson (Publ) A dpd system with multiple transmitter paths
ES2363358B1 (es) 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
WO2011057144A2 (en) 2009-11-06 2011-05-12 La Jolla Institute For Allergy And Immunology Methods for modulating lif activity, treating immune disorders and diseases, and stimulatings immune responses
CN102167742B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗her2单克隆抗体、其制备方法及用途
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
TWI486172B (zh) 2013-11-08 2015-06-01 Univ Chang Gung 鼻咽癌治療的醫藥

Also Published As

Publication number Publication date
JP6289906B2 (ja) 2018-03-07
JP2017019775A (ja) 2017-01-26
US10968273B2 (en) 2021-04-06
EP2556091A1 (en) 2013-02-13
BR112012025517B1 (pt) 2021-08-31
EA036698B1 (ru) 2020-12-09
PT2556091T (pt) 2017-01-03
SG184429A1 (en) 2012-11-29
HK1180702A1 (zh) 2013-10-25
HK1223384A1 (zh) 2017-07-28
CA2797257A1 (en) 2011-10-13
EA202092276A3 (ru) 2021-04-30
IL241952A (en) 2017-10-31
IL254664B (en) 2022-03-01
KR20170125137A (ko) 2017-11-13
EP2371860A1 (en) 2011-10-05
CN109320609A (zh) 2019-02-12
BR112012025517A2 (pt) 2017-11-28
IL222270A (en) 2016-06-30
EA202092276A2 (ru) 2021-01-29
US20190119373A1 (en) 2019-04-25
SMT201600468T1 (it) 2017-03-08
JP2013523796A (ja) 2013-06-17
LT2556091T (lt) 2016-12-27
MX365054B (es) 2019-05-21
AU2011237922B2 (en) 2014-07-10
WO2011124566A1 (en) 2011-10-13
KR20200119344A (ko) 2020-10-19
JP6483059B2 (ja) 2019-03-13
RS55539B1 (sr) 2017-05-31
CY1119451T1 (el) 2018-03-07
KR20190061098A (ko) 2019-06-04
MX2012011636A (es) 2013-04-03
US20130142808A1 (en) 2013-06-06
HK1208469A1 (en) 2016-03-04
IL222270A0 (en) 2012-12-31
KR20180078352A (ko) 2018-07-09
EA201201373A1 (ru) 2013-04-30
US20150139989A1 (en) 2015-05-21
AU2011237922A1 (en) 2012-11-01
PL2556091T3 (pl) 2017-04-28
IL254664A0 (en) 2017-11-30
HRP20161736T1 (hr) 2017-02-10
CN103797031A (zh) 2014-05-14
EA036698B9 (ru) 2021-02-25
KR20130121679A (ko) 2013-11-06
ES2608699T3 (es) 2017-04-12
KR102294207B1 (ko) 2021-08-26
EP3045473A1 (en) 2016-07-20
EP2556091B1 (en) 2016-09-28
HUE030578T2 (en) 2017-06-28
DK2556091T3 (en) 2017-01-16
US8926956B2 (en) 2015-01-06

Similar Documents

Publication Publication Date Title
IL254664A0 (en) An antibody that recognizes human leukemia inhibitory factor (lif) and the use of anti-lif antibodies in the treatment of diseases associated with unwanted cell proliferation
CY2019008I1 (el) Χρηση τροποποιημενων απο χιμαιρικο αντιγονικο υποδοχεα τ κυτταρων στη θεραπευτικη αγωγη καρκινου
EP3043819A4 (en) Anti-vstm5 antibodies and the use thereof in therapy and diagnosis
SG178991A1 (en) Anti-gitr antibodies
HK1198469A1 (en) Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease -icos
IL228813B (en) A polypeptide containing a first and second immunoglobulin each containing a single variable site and its use in the treatment of diseases
CA2840307C (en) Progenitor cells of mesodermal lineage
WO2011126864A3 (en) Cancer treatment with recombinant vector
HK1163119A1 (en) Anti cxcr4 antibodies and their use for the treatment of cancer cxcr4
ZA201307641B (en) Human tissue factor antibody and uses thereof
HK1208629A1 (en) Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency hgh-xten
IL223667B (en) 4a100s antibodies and medical uses thereof
HK1179997A1 (en) Neuregulin antagonists and use thereof in treating cancer
PL2668205T3 (pl) Peptydy pochodzące z ludzkiej laktoferyny i ich zastosowanie
EP2632939A4 (en) CANCER TARGETING PEPTIDES AND USES THEREOF IN THE TREATMENT AND DIAGNOSIS OF CANCER
EP2744786A4 (en) SUBSTITUTED 2-IMIDAZOLIDINONE AND 2-IMIDAZOLONE AND THEIR USE IN THE TREATMENT OF CANCER
EP3052109B8 (en) Therapy with cells from human placenta and hematopoietic cells
ZA201401800B (en) Novel plant defensins and use in the treatment of proliferative diseases
DK2665746T3 (en) Antibodies against the s100p protein for the treatment and diagnosis of cancer
GB201015789D0 (en) Peptides and their use in the treatment
ZA201309332B (en) Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer
GB201117876D0 (en) Peptides and their use in treatment
GB201001170D0 (en) Novel peptides and their use in therepy and diagnosis